Europäische Union - Deutsch - EMA (European Medicines Agency)

intervet international bv - azagly-nafarelin - hormone und analoga der hypophyse und des hypothalamus - dogs; salmonidae (salmonid fish) - weiblichen lachsartigen fischen wie atlantischer lachs (salmo salar), regenbogenforelle (oncorhynchus mykiss), bachforelle (salmo trutta) und arctic charr (salvelinus alpinus)die induktion und synchronisation der ovulation zur produktion von augen-eier und braten. hunde (hündinnen)prävention der funktion der gonaden bei den hündinnen über langfristige blockade der gonadotropin-synthese.

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz - sitagliptin hydrochloride monohydrate - filmtablette - 25 mg - sitagliptin hydrochloride monohydrate 28.343 mg - sitagliptin

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz - sitagliptin hydrochloride monohydrate - filmtablette - 50 mg - sitagliptin hydrochloride monohydrate 56.685 mg - sitagliptin

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz - sitagliptin hydrochloride monohydrate - filmtablette - 100 mg - sitagliptin hydrochloride monohydrate 113.37 mg - sitagliptin

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurogenerics afgekort "e.g." - sitagliptin hydrochloride - filmtablette - 25 mg - sitagliptin hydrochloride 27.238 mg - sitagliptin

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurogenerics afgekort "e.g." - sitagliptin hydrochloride - filmtablette - 50 mg - sitagliptin hydrochloride 54.475 mg - sitagliptin

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurogenerics afgekort "e.g." - sitagliptin hydrochloride - filmtablette - 100 mg - sitagliptin hydrochloride 108.95 mg - sitagliptin

Europäische Union - Deutsch - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Europäische Union - Deutsch - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - sitagliptin hydrochloride monohydrate - filmtablette - 25 mg - sitagliptin hydrochloride monohydrate 28.35 mg - sitagliptin